drugset / Trial / NCT03407859
Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
Phase 0
Unknown
100 enrolled
Zhujiang Hospital
Nanfang Hospital, Southern Medical University · collab
NaSequentialOpen-labelTreatment
Summary
CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients. CD20/CD22/CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19-negative relapse of B-ALL. Thus sequential treatment with CD20/CD22/CD10-CART after CD19-CART treatment in relapsed/refractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time.
Timeline
- Start
- 2016-01-18
- Primary completion
- 2024-12-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T | Cell therapy | — | — |
| Subject | CD20/CD22/CD10-CART | Cell therapy | — | — |